外泌体非编码RNA在肝癌液体活检中的研究进展

国际肿瘤学杂志››2019,Vol. 46››Issue (6): 378-381.doi:10.3760/cma.j.issn.1673-422X.2019.06.014

外泌体非编码RNA在肝癌液体活检中的研究进展

张芳雍,吴帆

暨南大学医学院附属广州红十字会医院普通外科510220

出版日期:2019-06-08发布日期:2019-07-11
通讯作者:吴帆，Email: wufan7911@ext.jnu.edu.cn E-mail:wufan7911@ext.jnu.edu.cn
基金资助:

广东省自然科学基金（2014A030313654）；广东省医学科学技术研究基金（A2018028）；广州市科技计划（201804010025）

Research progress on exosomederived noncoding RNAs in liquid biopsy of hepatocelluar carcinoma

Zhang Fangyong, Wu Fan

Department of General Surgery, Guangzhou Red Cross Hospital, Medical College, Jinan University, Guangzhou 510220, China

Online:2019-06-08Published:2019-07-11
Contact:Wu Fan, Email: wufan7911@ext.jnu.edu.cn E-mail:wufan7911@ext.jnu.edu.cn
Supported by:

Natural Science Foundation of Guangdong Province of China (2014A030313654); Medical Scientific Research Foundation of Guangdong Province of China (A2018028); Science and Technology Planning Project of Guangzhou Municipal Bureau of China (201804010025)

摘要/Abstract

摘要：外泌体内含有丰富的非编码RNA，且具有重要的基因调控功能，在肝癌的发生发展中起重要作用。外泌体非编码RNA有望成为新型的肝癌液体活检标志物，为肝癌的早期诊断、早期治疗提供新手段。尽管当前外泌体非编码RNA的临床应用仍存在不足，但随着研究的深入，外泌体非编码RNA在肝癌的诊断、个性化治疗及预后评估等方面将发挥越来越重要的作用。

关键词:肝肿瘤,液体活检,外泌体,非编码RNA

Abstract:Exosomes contain ample non-coding RNAs， which mainly function as regulating gene expression and play key roles in the occurrence and development of hepatocellular carcinoma. Exosomal non-coding RNAs are expected to become a new biopsy marker for hepatocellular carcinoma, providing a new means for early diagnosis and early treatment of hepatocellular carcinoma.Although the clinical application of exosomal noncoding RNAs is still insufficient at present, exosomal noncoding RNAs will play an increasingly important role in the diagnosis, personalized treatment and prognosis evaluation of hepatocellular carcinoma with the deepening of research.

Key words:Liver neoplasms,Liquid biopsy,Exosomes,Non-coding RNA

张芳雍, 吴帆. 外泌体非编码RNA在肝癌液体活检中的研究进展[J]. 国际肿瘤学杂志, 2019, 46(6): 378-381.

Zhang Fangyong, Wu Fan. Research progress on exosomederived noncoding RNAs in liquid biopsy of hepatocelluar carcinoma[J]. Journal of International Oncology, 2019, 46(6): 378-381.

参考文献

［1］ Kaikkonen MU, Adelman K. Emerging roles of noncoding RNA transcription［J］. Trends Biochem Sci, 2018, 43(9): 654-667. DOI: 10.1016/j.tibs.2018.06.002. ［2］ Li Y, Zheng Q, Bao C, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis［J］. Cell Res, 2015, 25(8): 981-984. DOI: 10.1038/cr.2015.82. ［3］ Huang X, Yuan T, Liang M, et al. Exosomal miR-1290 and miR-375 as prognostic markers in castrationresistant prostate cancer［J］. Eur Urol, 2015, 67(1): 33-41. DOI: 10.1016/j.eururo.2014.07.035. ［4］ Wang H, Hou L, Li A, et al. Expression of serum exosomal micro-RNA-21 in human hepatocellular carcinoma［J］. Biomed Res Int, 2014, 2014: 864894. DOI: 10.1155/2014/864894. ［5］ Sugimachi K, Matsumura T, Hirata H, et al. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation［J］. Br J Cancer, 2015, 112(3): 532-538. DOI: 10.1038/bjc.2014.621. ［6］ Lee YR, Kim G, Tak WY, et al. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma［J］. Int J Cancer, 2018, 144(6): 1444-1452. DOI: 10.1002/ijc.31931. ［7］ Sohn W, Kim J, Kang SH, et al. Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma［J］. Exp Mol Med, 2015, 47: e184. DOI: 10.1038/emm.2015.68. ［8］ Xue X, Zhao Y, Wang X, et al. Development and validation of serum exosomal microRNAs as diagnostic and prognostic biomarkers for hepatocellular carcinoma［J］. J Cell Biochem, 2019, 120(1): 135-142. DOI: 10.1002/jcb.27165. ［9］ Qu Z, Wu J, Wu J, et al. Exosomal miR-665 as a novel minimally invasive biomarker for hepatocellular carcinoma diagnosis and prognosis［J］. Oncotarget, 2017, 8(46): 80666-80678. DOI: 10.18632/oncotarget.20881. ［10］ Wang Y, Zhang C, Zhang P, et al. Serum exosomal microRNAs combined with alphafetoprotein as diagnostic markers of hepatocellular carcinoma［J］. Cancer Med, 2018, 7(5): 1670-1679. DOI: 10.1002/cam4.1390. ［11］ Liu W, Hu J, Zhou K, et al. Serum exosomal miR125b is a novel prognostic marker for hepatocellular carcinoma［J］. Onco Targets Ther, 2017, 10: 3843-3851. DOI: 10.2147/OTT.S140062. ［12］ Tang J, Li Y, Liu K, et al. Exosomal miR-9-3p suppresses HBGF-5 expression and is a functional biomarker in hepatocellular carcinoma［J］. Minerva Med, 2018, 109(1): 15-23. DOI: 10.23736/S0026-4806.17.05167-9. ［13］ Shi M, Jiang Y, Yang L, et al. Decreased levels of serum exosomal miR638 predict poor prognosis in hepatocellular carcinoma［J］. J Cell Biochem, 2018, 119(6): 4711-4716. DOI: 10.1002/jcb.26650. ［14］ Revenfeld AL, Baek R, Nielsen MH, et al. Diagnostic and prognostic potential of extracellular vesicles in peripheral blood［J］. Clin Ther, 2014, 36(6): 830-846. DOI: 10.1016/j.clinthera.2014.05.008. ［15］ Dong L, Lin W, Qi P, et al. Circulating long RNAs in serum extracellular vesicles: their characterization and potential application as biomarkers for diagnosis of colorectal cancer［J］. Cancer Epidemiol Biomarkers Prev, 2016, 25(7): 1158-1166. DOI: 10.1158/1055-9965.EPI-16-0006. ［16］ Zhou R, Chen KK, Zhang J, et al. The decade of exosomal long RNA species: an emerging cancer antagonist［J］. Mol Cancer, 2018, 17(1): 75. DOI: 10.1186/s12943-018-0823-z. ［17］ Sun L, Su Y, Liu X, et al. Serum and exosome long non coding RNAs as potential biomarkers for hepatocellular carcinoma［J］. J Cancer, 2018, 9(15): 2631-2639. DOI: 10.7150/jca.24978. ［18］ Li B, Mao R, Liu C, et al. LncRNA FAL1 promotes cell proliferation and migration by acting as a CeRNA of miR-1236 in hepatocellular carcinoma cells［J］. Life Sci, 2018, 197: 122-129. DOI: 10.1016/j.lfs.2018.02.006. ［19］ Zhang C, Yang X, Qi Q, et al. lncRNAHEIH in serum and exosomes as a potential biomarker in the HCVrelated hepatocellular carcinoma［J］. Cancer Biomark, 2018, 21(3): 651-659. DOI: 10.3233/CBM-170727. ［20］ Xu H, Chen Y, Dong X, et al. Serum exosomal long noncoding RNAs ENSG00000258332.1 and LINC00635 for the diagnosis and prognosis of hepatocellular carcinoma［J］. Cancer Epidemiol Biomarkers Prev, 2018, 27(6): 710-716. DOI: 10.1158/1055-9965.EPI-17-0770. ［21］ Hou Y, Yu Z, Tam NL, et al. Exosomerelated lncRNAs as predictors of HCC patient survival: a prognostic model［J］. Am J Transl Res, 2018, 10(6): 1648-1662. ［22］ Bao C, Lyu D, Huang S. Circular RNA expands its territory［J］. Mol Cell Oncol, 2016, 3(2): e1084443. DOI: 10.1080/23723556.2015.1084443. ［23］ Zhang X, Xu Y, Qian Z, et al. circRNA_104075 stimulates YAPdependent tumorigenesis through the regulation of HNF4a and may serve as a diagnostic marker in hepatocellular carcinoma［J］. Cell Death Dis, 2018, 9(11): 1091. DOI: 10.1038/s41419-018-1132-6. ［24］ Zhang C, Zhang C, Lin J, et al. Circular RNA hsa_circ_0091579 serves as a diagnostic and prognostic marker for hepatocellular carcinoma［J］. Cell Physiol Biochem, 2018, 51(1): 290-300. DOI: 10.1159/000495230. ［25］ Zhang X, Zhou H, Jing W, et al. The circular RNA hsa_circ_0001445 regulates the proliferation and migration of hepatocellular carcinoma and may serve as a diagnostic biomarker［J］. Dis Markers, 2018, 2018: 3073467. DOI: 10.1155/2018/3073467. ［26］ Matboli M, Shafei AE, Ali MA, et al. circRNAs (hsa_circ_00156, hsa_circ _000224, and hsa_circ _000520) are novel potential biomarkers in hepatocellular carcinoma［J］. J Cell Biochem, 2019, 120(5): 7711-7724. DOI: 10.1002/jcb.28045. ［27］ Li X, Shen M. Circular RNA hsa_circ_103809 suppresses hepatocellular carcinoma proliferation and invasion by sponging miR620［J］. Eur Rev Med Pharmacol Sci, 2019, 23(2): 555-566. DOI: 10.26355/eurrev_201902_16868. ［28］ Wang G, Liu W, Zou Y, et al. Three isoforms of exosomal circPTGR1 promote hepatocellular carcinoma metastasis via the miR449aMET pathway［J］. EBioMedicine, 2019, 40: 432-445. DOI: 10.1016/j.ebiom.2018.12.062.

[1]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[2]	彭琴, 蔡玉婷, 王伟.KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[3]	刘博翰, 黄俊星.液体活检技术在食管鳞状细胞癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 105-108.
[4]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹.结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[5]	向玉玲, 谭佳杰, 熊远果, 赵丽蓉, 黎晨, 张洪.脱水淫羊藿素对肝癌细胞增殖、迁移和凋亡的影响[J]. 国际肿瘤学杂志, 2023, 50(9): 513-519.
[6]	张渊, 白芷玉, 李琪, 冯勤梅.外泌体在恶性肿瘤中的研究现状[J]. 国际肿瘤学杂志, 2023, 50(8): 484-488.
[7]	李佳璇, 封颖璐.糖皮质激素受体在肝癌细胞生长中的作用机制[J]. 国际肿瘤学杂志, 2023, 50(4): 241-243.
[8]	和婷, 王希, 张惠中, 刘昕阳, 王会平, 董轲.血清TIM-3对肝癌患者诊断价值的研究[J]. 国际肿瘤学杂志, 2022, 49(9): 537-542.
[9]	张俊鹏, 于燕燕, 李宝生.lncRNA、circRNA调控食管鳞状细胞癌放化疗敏感性的作用机制[J]. 国际肿瘤学杂志, 2022, 49(3): 185-189.
[10]	李洪宇, 乌新林.外泌体与结直肠癌肝转移[J]. 国际肿瘤学杂志, 2022, 49(12): 749-753.
[11]	张玉敏, 赵现伟, 何前进, 陈杰能.超声造影联合血清CXCL8、CXCR2在原发性肝癌经导管动脉化疗栓塞术后疗效评估中的价值分析[J]. 国际肿瘤学杂志, 2022, 49(10): 592-596.
[12]	王文浩, 孙希瑞, 刘锦, 孙秀梅.肿瘤相关成纤维细胞在乳腺癌发生与发展中的作用[J]. 国际肿瘤学杂志, 2022, 49(10): 615-618.
[13]	狄伟华, 赵雪梅.DNA损伤修复在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(10): 635-638.
[14]	张琬琛, 徐加杰, 张李卓, 葛明华.外泌体-环状RNA在肿瘤诊治中的临床意义[J]. 国际肿瘤学杂志, 2021, 48(9): 549-552.
[15]	杜佳航, 陈栋, 陈耀庭.三氧化二砷抗肝癌机制及其在肝癌治疗中的研究[J]. 国际肿瘤学杂志, 2021, 48(9): 572-.